LGALS1 and metastatic neoplasm: However, among patients without metastatic disease at sample procurement who subsequently developed metastatic disease during follow-up, there was no correlation between serum galectin-1 level (Figure 5A, p = 0.3505), or when high or low galectin-1 was combined into abnormal galectin-1 level (Figure 5B, p = 0.3169) and development of future metastasis.